Today: 29 June 2026
TUI stock drops as summer bookings slip, muting record Q1 profit boost
10 February 2026
1 min read

TUI stock drops as summer bookings slip, muting record Q1 profit boost

Frankfurt, Feb 10, 2026, 13:09 CET — Regular session

  • TUI shares slipped midway through the session, after the travel company pointed to a modest dip in booked revenue for summer 2026.
  • The company just logged its strongest first-quarter underlying EBIT since merging in 2014, and kept its full-year guidance unchanged.
  • Late-booking trends and how profits shape up for the peak summer stretch are grabbing investor attention.

TUI AG slipped 3.5% to 9.02 euros in Frankfurt on Tuesday, as the market digested a robust Q1 but flagged lighter booked revenue for the summer. Shares touched an intraday low of 8.60 euros.

This is a big deal—summer’s when Europe’s largest tour operator usually rakes in the bulk of its profits. Even slight shifts in booking trends can knock on to prices, plane loads, and how full hotels get.

TUI wants to dial back on “own-risk” capacity — those seats and rooms it locks in early — and instead lean harder on dynamic packages via apps and outside suppliers. On paper, the risk profile shrinks. The flip side: growth numbers can get bumpier from one week to the next.

TUI’s quarterly numbers showed underlying EBIT at 77.1 million euros, with revenue holding steady at 4.9 billion euros for the first quarter. Net debt edged down to 3.6 billion euros. The company stuck to its full-year targets—revenue up 2% to 4%, underlying EBIT up 7% to 10%. Booked revenue slipped, down 1% for winter 2025/26 and 2% lower for summer 2026.

Chief executive Sebastian Ebel assured shareholders the group’s year was off to a “good start,” booking numbers for both winter and summer are “robust” and “meet our expectations.” Chief financial officer Mathias Kiep, for his part, pointed to a stronger financial profile and a reduction in net debt. TUI Group

Jamie Rollo at Morgan Stanley flagged the first quarter as “seasonally small” for TUI—a period prone to swings—but pointed out the stronger kickoff now leaves the company needing “+7% EBIT for the rest of the year.” Rollo also thought the shares would likely see a “slightly negative” response, citing softer numbers from the Markets + Airline segment. Investing.com Nigeria

TUI is noticing a change in European travel patterns, according to Ebel. Demand for trips to the United States has dropped off “significantly,” while more customers are opting for destinations in the Emirates and Asia, and interest in the Caribbean is on the rise. The Guardian

For investors, there’s a clear risk: if last-minute booking trends pick up pace into spring, airlines and hotels could be pushed to slash prices just to fill seats and rooms. Margins are already vulnerable—rising fuel bills, sudden operational snags, or unexpected weather can bite fast in travel. TUI flagged macro and geopolitical uncertainty as well.

Investors will be watching Tuesday’s annual general meeting for a dividend vote, with the next key date for the market coming up on May 13, when the half-year report lands.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • UK's Scancell proposes reverse merger with Nasdaq-listed Neuphoria to boost US investor presence
    June 29, 2026, 10:20 AM EDT. UK-based biotech Scancell Holdings has proposed a reverse merger with Neuphoria Therapeutics, listed on Nasdaq, to secure a U.S. listing and enhance its profile among American specialist investors. The all-stock deal details remain undisclosed. Neuphoria's shares have steeply declined after its lead drug soclenicant failed a late-stage social anxiety trial, prompting a strategic review and suitor interest, including offers from hedge fund Lynx1 Master Fund. Neuphoria maintains a partnership with Merck, with potential milestone revenues of up to $450 million. Meanwhile, Scancell aims to advance its own melanoma and cancer vaccine candidates, seeking equity and debt financing for its phase 3 studies. The deal appears driven more by Scancell's desire for Nasdaq access than Neuphoria's pipeline assets.
US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data
Previous Story

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop